Cure My Disease

Don't miss your cure!

 Log in / Sign up

Aloe vera vs. steroid: which tames oral lichen planus?

NCT ID NCT07792512

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether aloe vera gel can relieve the pain and sores of oral lichen planus as effectively as a standard corticosteroid gel. Adults aged 25 to 60 with confirmed painful oral lichen planus will apply either aloe vera or the steroid four times daily for two months. Researchers will measure changes in lesion size and pain at several points, and also check how each treatment affects levels of tumor necrosis factor alpha, an inflammation marker, in saliva.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aloe vera gel (70% mucilage) compared with topical corticosteroid creams (triamcinolone acetonide 0.1% and hydrocortisone 2.5%)
What this could lead to
If aloe vera works as well as the standard steroid, people with oral lichen planus could have a gentler, plant-based option to ease pain and mouth sores.
What could go wrong
This is a small, early-stage comparison with only 24 participants, so results may not apply to everyone. Aloe vera may not match the steroid's effect, and the study does not test long-term safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

24 people

The number who actually took part.

Started

Jan 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Both genders, aged ranged from 25 to 60 years. * Clinically proven painful symptomatic forms of OLP confirmed by the presence of red or erythematous changes, or shallow ulcerations with fine lacy lines at the periphery of the lesion accentuated by stretching and not eliminated by rubbing (Wickham's striae) * Histopathological proven symptomatic OLP Exclusion Criteria: * History of drug induced lichenoid lesion. * Presence of systemic conditions as; serious active or recurrent infections, malignancy, diabetes mellitus, hypertension, or significant heart, liver, or renal diseases. Assessed using medical questionnaire guided by Cornell Medical Index. * Smoking * Known hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation as mentioned in history * Pregnancy or breast-feeding. * History of previous treatments potentially effective on OLP such as antimalarial agents, retinoid, corticosteroids, or immunosuppressive drugs from less than 2 weeks for topical medications, and 4 weeks for systemic medications prior to starting the study. * Loss of pliability or flexibility in the tissues involved by the lesions of OLP. * Histological signs of epithelial dysplasia or lichenoid lesions within the biopsied sites. * Patients with extensive skin lesions and indicated for systemic corticosteroids. * Vulnerable groups (Handicapped, orphans or prisoners)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Oral lichen planus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lichen planus, oral

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oral lichen planus Tumor necrosis factor-alpha

Contacts and locations

Locations

  • Ainshams University

    Cairo, Cairo Governorate, 01234, Egypt

  • Faculty Of Dentistry, Ainshams University.

    Al ‘Abbāsīyah, Cairo Governorate, 01234, Egypt

  • Faculty Of Dentistry, Ainshams University.

    Al ‘Abbāsīyah, Cairo Governorate, Egypt

  • Faculty Of Dentistry, Ainshams University.

    Cairo, Egypt

  • Faculty of dentistry Ainshams University

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.